
Consolidation, specialty growth, and integrated networks are multiplying the entities manufacturers must classify, just as the IRA, 340B, and Medicaid rules raise the cost of getting any one of them wrong.
Manasi Salgaonkar is a pharmaceutical market access professional specializing in membership and chargebacks — the operations that underpin drug pricing, contract eligibility, and discount adjudication across the pharmaceutical supply chain. She holds a Master’s in Healthcare Decision Analysis from the University of Southern California and a Master’s in Bioanalytical Sciences, with earlier experience in clinical research. She serves as a peer reviewer for journals in the managed care and outcomes research space, including the American Journal of Managed Care, and writes on data governance, pricing, and market access for industry and policy publications.

Consolidation, specialty growth, and integrated networks are multiplying the entities manufacturers must classify, just as the IRA, 340B, and Medicaid rules raise the cost of getting any one of them wrong.